Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

Hemmi, 2002, Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway, Nat Immunol, 3, 196, 10.1038/ni758 Gibson, 2002, Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod, Cellular Immunol, 218, 74, 10.1016/S0008-8749(02)00517-8 Miller, 1992, Imiquimod applied topically, Int J Immunopharmacol, 21, 1, 10.1016/S0192-0561(98)00068-X Marks, 2001, Imiquimod 5% cream in the treatment of superficial basal cell carcinoma, J Am Acad Dermatol, 44, 807, 10.1067/mjd.2001.113689 Geisse, 2002, Imiquimod 5% cream for the treatment of superficial basal cell carcinoma, J Am Acad Dermatol, 47, 390, 10.1067/mjd.2002.126215 Beutner, 1999, Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream, J Am Acad Dermatol, 41, 1002, 10.1016/S0190-9622(99)70261-6 Shumack, 2002, Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma, Arch Dermatol, 138, 1165, 10.1001/archderm.138.9.1165 Sterry, 2002, Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma, Br J Dermatol, 147, 1227, 10.1046/j.1365-2133.2002.05069.x Newcomb, 1998, Two-sided confidence intervals for the single proportion, Stat Med, 17, 857, 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E Newcomb, 1998, Interval estimation for the differences between dependent proportions, Stat Med, 17, 873, 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I